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Of women with early breast cancer who receive chemotherapy 70 - 
80% do not benefit from the treatment, but 1 - 5% with an ‘excellent’ 
prognosis experience recurrence and should have been given the 
benefit of the extra therapy. More accurate markers are needed to 
reflect the disease prognosis and predict response to treatment.
A prognostic marker is associated with clinical outcome 
irrespective of treatment given, e.g. tumour grade, size and lymph 
node involvement. A predictive marker, e.g expression of estrogen 
or progesterone receptors (ER or PR), predicts clinical benefit from 
a particular treatment. Online guidelines help refine the situation. 
The Adjuvant!online and St Gallen guidelines are commonly used. 
Despite the above, many women with early breast cancer will receive 
unnecessary adjuvant treatment.
An ideal marker gives information about prognosis and predicts 
response to treatment. Can gene profiling answer this need? Micro-
array analysis is commonly used in genetics laboratories. The tumour 
is broken down and a DNA micro-array probe is programmed to 
extract complementary mRNA. Thousands of genes may be extracted 
at precise locations. Polymerase chain reaction (PCR) amplification 
then ensures that enough mRNA is available for analysis.
In 2000, Perou et al.1 analysed 8 102 genes in 65 breast specimens. 
Some were pathological specimens (including carcinoma and fibro-
adenoma) and some were normal breast tissue. Normal breast 
tissue and fibro-adnomas had a similar genetic pattern. Tissue from 
primary and metastatic lesions from the same individuals showed 
the same pattern of gene expression. The authors grouped breast 
cancers into four groups: ER+ve luminal A, ER+ve luminal B (poorer 
prognosis), basal-like (triple –ve), and Erb B2+.
Van’t Veer et al.,2 from the Netherlands, looked at the gene profile 
of 98 primary breast cancers: 34 had developed metastatic disease in 
less than 5 years, and 44 had no evidence of metastatic disease after 
5 years. They tested 5 000 genes and identified 70 that were most 
consistently associated with tumour behaviour. They extended their 
research to look at a total of 295 patients.3
Paik et al.4 tested genes they predicted would be the most 
important in determining carcinoma behaviour. A 21-gene probe was 
tested on 668 tumours from the National Surgical Adjuvant Breast 
and Bowel Project (NSABP) Trial, which looked at ER+ve patients 
treated with tamoxifen. A recurrence score (RS) was generated and 
compared with the outcome of the patients. A reasonable correlation 
between RS and the development of metastases was noted.
Both groups have done further validation studies looking at 
patients with no adjuvant treatment (the numbers are limited), 
patients receiving aromatase inhibitors, and whether genetic profiling 
can be used to predict the response to chemotherapy.
At least 5 micro-array gene assays have been developed for 
commercial use; the 70-gene micro-array assay (Mammaprint) and the 
OncoDx are available in this country. The Mammaprint utilises fresh 
carcinoma tissue from a core taken at the time of primary surgery. It 
is a decisive assay: 97% of patients are stratified into high or low risk 
of experiencing recurrence. The OncoDx is only validated for ER+ve 
patients and divides patients into low risk, intermediate risk or high 
risk of recurrence. The assay can be done on preserved tissue so can be 
requested postoperatively.
When micro-array gene analysis has been used as a predictive tool, 
30 - 45% of patients have had their treatment modified: the majority 
have been advised not to have chemotherapy.
Micro-array analyses are not routinely used in South Africa.  Their 
cost (R20 000 - R30 000) is currently not covered by most medical aids. 
Adopting the technique as a routine predictive marker is controversial. 
The EGAPP working group (Evaluation of Genomic Applications 
in Practice and Prevention)5 noted that independent tests of validity 
showed that 12 - 19% of samples failed owing to tissue sampling/
processing, and that the initial validation studies were done on whole 
tumour specimens and not core biopsies. Of relevance to South Africa 
is that the study populations of the validation studies were patients of 
predominantly European descent. They noted the lack of long-term 
follow-up with the comment ‘No studies determined whether use of 
assay in place of or in addition to current clinico-pathological markers 
… improves outcomes based on traditional management.’
Other groups have a guarded approach to the use of genetic 
profiling. The American Society of Clinical Oncology (ASCO) 
guidelines include ‘[In] Node–ve, ER+ve pts, Onco Dx may be used 
to predict risk of recurrence … and identify patients ... [who will get 
the] most therapeutic response to tamoxifen and may not [therefore] 
require chemo.’ The 2009 St Gallen guidelines were vaguer: ‘[The] 
use of a validated multi-gene profiling assay warranted as adjunct … 
in cases where indication for chemotherapy remains uncertain.’ The 
FDA have approved MammaPrint for use as a prognostic tool but not 
‘to predict or direct response to therapy or select optimal therapy’. 
The South Africa Oncology Consortium guidelines suggest that it 
should be considered for ‘ER+ve, HER2-ve tumours 0.5 - 5 cm in size 
and node negative or a micrometastasis <2 mm’.
A randomised study to ascertain whether the use of genetic 
profiling improves patient outcome is needed. Two trials should 
provide us with the answers. The Trial Assigning IndividuaLized 
Options for Treatment (Rx) (TAILORx) will use OncoDx to assign 
patients into 3 groups.  Patients with a low-risk score will be managed 
with hormonal therapy alone, the intermediate group will be 
randomised to chemo/no chemo, and those with a high RS hormone 
level will be treated with chemotherapy. The MINDACT trial 
(Microarray In Node-negative and 1 to 3 positive lymph node Disease 
may Avoid ChemoTherapy) uses Adjuvant!Online and MammaPrint 
to classify patients as at high or low risk. Patients deemed at high risk 
will receive chemotherapy; those with a low risk of recurrence will 
have no chemotherapy. When the results are discordant they will be 
randomised to chemotherapy or no chemotherapy.
Genetic profiling will become a common tool when deciding 
whether or not patients should receive chemotherapy and may be 
extended into predicting response to surgery. Until we have clear 
evidence that it improves patient survival, its use should be limited.
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